The phase 3 trial AURA 3 demonstrated that osimertinib significantly prolonged PFS compared to platinum-based chemotherapy in advanced EGFR-mutant NSCLC patients with the T790M mutation who had developed resistance to first- and second-generation EGFR-TKI treatments [9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.